- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00421850
Using Networks, Informatics, Technology, and Education in Care for People With Diabetes
UNITED Planned Care for People With Diabetes
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The problem: The quality of diabetes care is highly variable, with some patients receiving sub-optimal care. Best practice is ideally described by research findings. Most providers are not aware of research findings. Traditional continuing medical education (CME) and dissemination of practice guidelines have failed to reduce variation around best practice.
A proposed solution: We hypothesize that practitioners that receive evidence-based information addressing a specific deficiency in their practice, in a timely fashion and at the point-of-care, are more likely to improve the quality of their diabetes care. To test this hypothesis we suggest the following randomized controlled trial.
Randomized trial
Participants: Primary care teams
Intervention: (UNITED PLANNED CARE MODEL)In the setting of the Planned Care Model, for providers and their teams assigned to this intervention, a Diabetes Electronic Management System will produce individualized performance reports on all health care teams. Specific performance gaps will be identified and will trigger two actions: 1) Specific messages will be forwarded to the team addressing a performance gap. 2) A diabetologist will provide counsel and support specific to these deficiencies. (e.g. based on performance reports generated by DEMS, an individual provider who has a patient with a performance gap of an LDL cholesterol> 150 not on medications, would get specific evidence based message about goal LDL cholesterol in patients with diabetes, & support/suggestions from the specialist)
Control (USUAL PLANNED CARE) In the setting of the Planned Care Model, providers and their team wills receive periodic information about cardiovascular risk reduction in diabetes but not specific to a patient?s performance gap. These teams will have access to the specialists using usual referral channels. None of these sources will be responding to these practitioners? performance gaps. There will be no proactive support or suggestions from the specialist.
Outcomes: 1) Processes (.e.g., frequency of lipid profile measurement); 2) Patient metabolic outcomes (.e.g., % of patients in the practice with LDL concentrations < 100 mg/dL); 3) Patient-centered outcomes (e.g., % of patients who suffered an atherosclerotic event); 4) CQI process and cost-effectiveness.
Significance:
A. Implement a Planned Care model in at least 3 primary care sites in Rochester-Kasson B. Pilot and Implement a structured specialty communication links and point of care evidence based messages in support of CME by telecommunication links to include DEMS.
C. Measure patient satisfaction with care delivery D. Measure provider and health care team satisfaction with care delivery E. Measure metabolic outcomes of patients participating in the project F. Measure demographics and other co-morbidities for patients participating in the project G. Audit for performance metrics, patients outcomes yearly after intervention and complete statistical assessment in keeping with primary hypotheses of the project H. Provision of anonymized patient data in support of the assessment of the outcomes of the study
Studietyp
Inskrivning
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Minnesota
-
Rochester, Minnesota, Förenta staterna, 55905
- Mayo Clinic
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- All patients in primary care referred to Diabetes Educator
Studieplan
Hur är studien utformad?
Designdetaljer
- Tilldelning: Randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vad mäter studien?
Primära resultatmått
Resultatmått |
---|
Processes of clinical care for diabetes
|
Cardiovascular risk as determined by UKPDS Risk
|
Metabolic outcomes (HgbA1c)
|
Metabolic outcomes (LDL Cholesterol)
|
Metabolic Outcomes (Systolic Blood Pressure)
|
Sekundära resultatmått
Resultatmått |
---|
Health Care Utlization and Costs
|
Satisfaction (Provider and Health Team)
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Steven A. Smith, M.D., Mayo Clinic
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 1938-00
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Diabetes mellitus
-
Medical College of WisconsinMedical University of South CarolinaAvslutadDiabetes mellitus | Typ 2-diabetes mellitus | Vuxendiabetes mellitus | Icke-insulinberoende diabetes mellitus | Noninsulinberoende diabetes mellitus, typ IIFörenta staterna
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AvslutadDiabetes mellitus, typ 1 | Typ 1-diabetes | Diabetes typ 1 | Typ 1-diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinberoende | Ungdomsdiabetes | Diabetes, autoimmun | Insulinberoende diabetes mellitus 1 | Diabetes mellitus, insulinberoende, 1 | Diabetes mellitus, spröd | Diabetes mellitus, juvenil-debut och andra villkorFörenta staterna
-
Guang NingRekryteringTyp 2-diabetes mellitus | Typ 1 diabetes mellitus | Monogenetisk diabetes | Pankreatogen diabetes | Läkemedelsinducerad diabetes mellitus | Andra former av diabetes mellitusKina
-
SanofiAvslutadTyp 1-diabetes mellitus-typ 2-diabetes mellitusUngern, Ryska Federationen, Tyskland, Polen, Japan, Förenta staterna, Finland
-
Hanmi Pharmaceutical Company LimitedOkändTyp 2 diabetes mellitus | Typ 1 diabetes mellitusFörenta staterna
-
Peking Union Medical College HospitalOkändTyp 2-diabetes mellitus | Typ 1-diabetes mellitus | Graviditetsdiabetes mellitus | Pankreatogen diabetes mellitus | Pregestationsdiabetes mellitus | Diabetespatienter i perioperativ periodKina
-
Leiden University Medical CenterAndaluz Health ServiceAvslutadDiabetes mellitus | Hälsobeteende | Självförmåga | Typ 2 diabetes mellitus | Typ 1 diabetes mellitusNederländerna, Spanien
-
Meir Medical CenterAvslutadDiabetes mellitus typ 2 | Diabetes mellitus, icke-insulinberoende | Diabetes mellitus, om oral hypoglykemisk behandling | Vuxen typ diabetes mellitusIsrael
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AvslutadDiabetes mellitus, typ 2 | Diabetes mellitus, typ II | Diabetes mellitus, vuxendebut | Diabetes mellitus, icke-insulinberoende | Diabetes mellitus, icke-insulinberoendeFörenta staterna
-
Medtronic DiabetesAvslutadTyp 1-diabetes mellitus | Typ 2 diabetes mellitusFörenta staterna
Kliniska prövningar på UNITED Planned Care
-
Ankara UniversityHar inte rekryterat ännuDysmenorré PrimärKalkon
-
Florida State UniversityUniversity of North Carolina, Chapel Hill; University of GeorgiaAnmälan via inbjudanMinskad risk för kardiovaskulära sjukdomarFörenta staterna
-
Florida State UniversityUniversity of Georgia; Florida A&M UniversityAvslutadKardiovaskulär riskfaktor
-
Xijing HospitalAvslutadPrimär axillär hyperhidrosKina
-
University of British ColumbiaSocial Sciences and Humanities Research Council of CanadaAvslutad
-
RenJi HospitalRekrytering
-
Chunrui LiNanjing IASO Biotechnology Co., LtdRekryteringPlasmacellleukemi | Återfall/refraktärt multipelt myelomKina
-
GE HealthcareAvslutadEkokardiografiFörenta staterna
-
Cellular Biomedicine Group Ltd.The First Affiliated Hospital with Nanjing Medical UniversityAvslutadEn fas 1-studie som utvärderar säkerhet och effekt av C-CAR011-behandling hos DLBCL-ämnen (C-CAR011)Refraktärt diffust stort B-cellslymfomKina
-
Zhejiang UniversityCarbiogene Therapeutics Co. Ltd.Har inte rekryterat ännuKlinisk prövning av autologa GPC3 CAR-T-celler (CBG166) terapi för avancerad hepatocellulär karcinomAvancerat hepatocellulärt karcinomKina